Implants, cocktails, and networking—all in the shadow of the Eiffel Tower.
Oldest Orthopedic Technology Conference: Implants 2018

From June 6-7, 2018 in Paris thought leaders in orthopedic technology will gather to discuss up-to-the-minute topics, including: How can collaboration between OEMs (original equipment manufacturers) and contract manufacturers yield innovation? Which technology/equipment supplier will be dominant? How is robotic assisted and navigation changing the nature of the industry by demanding new know-how and technologies? What is the future of minimally invasive surgery?
Ali Madani, CEO and founder of Avicenne and chair of the Implants 2018 conference in Paris told OTW, “We routinely discuss with a lot of decision makers within the industry: Industrials, contract manufacturing, private equity funds, and other consultants to create a strong program. We strive to select the topics that rank the highest on the executives’ agendas—anything that is new, emerging, undecided, where there is uncertainty, and possibly, conflicting views.”
“Take robotics for example. Some people are very enthusiastic about it and predict a booming market, with 20% of knee surgery in the U.S. to be robotic-assisted by 2025. Others are saying it will follow the same course as navigation, i.e., seduce enthusiastic, young surgeons, academic hospitals…but will peak and decreased just like navigation.”
And the top three reasons people should attend the event?
“First, education, with a global view of what’s happening in the industry, from the perspectives of many different leaders, experts and inspiring speakers. And the pre-workshop event, where I will share a summary of Avicenne’s latest research.”
“Second, the networking opportunities with attendees and speakers alike, from all over the world.”
“Third, there is an increasing visibility of the brand, products, etc. for people who elect to sponsor the event.”
Some of the Implants 2018 speakers include, Nicolas Pivert, restorative therapy group director, Pain & Spine Business Director at Medtronic; Mauro Malzanni, strategy and marketing director of Emerging Markets and Asia Pacific at Smith & Nephew; Jerry Jurkiewicz, chief executive officer, Orchid Orthopedic Solutions;Manuel Fuentes, regional business manager of Robotics and Total Joint Replacements, Eastern USA, OMNIlife science.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.